Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-17 | Modus Therapeutics Holding | Kallelse till årsstämma i Modus Therapeutics Holding | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-17 | Modus Therapeutics Holding | Notice to Annual General Meeting in Modus Therapeutics Holding | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Notice to Annual General Meeting in Modus Therapeutics HoldingThe shareholders of Modus Therapeutics Holding AB (publ) are invited to the annual general meeting on Friday, 17 May 2024, at 11.00 a.m., at Advokatfirman Vinge’s offices at Smålandsgatan 20, in Stockholm, Sweden. Right to participate and notice A shareholder who wishes to participate in the meeting must:
Nominee-registered shares A shareholder whose shares are nominee registered with a bank or other nominee must, in order to be entitled to participate at the meeting, re-register the shares in their own name so the shareholder is entered into the share register by Wednesday, 8 May 2024. Such registration may be temporary (so-called voting registration) and is requested from the nominee in accordance with the nominee’s procedures and in such time in advance as the nominee determines. Voting right registrations completed by the nominee not later than Monday, 13 May 2024 are taken into account when preparing the register of shareholders. Proxy etc. Shareholder represented by a proxy shall issue a power of attorney for the proxy. If the power of attorney is issued on behalf of a legal entity, a registration certificate or the equivalent indicating the authorized signatories of the legal entity must be enclosed. The original power of attorney, and any registration certificate or the equivalent document, should be sent to the company so that it is received not later than Thursday, 16 May 2024. Proxy forms are available at the company’s website www.modustx.com and will, upon request, be sent by regular mail to shareholders stating their postal address. Proposed agenda:
Proposed resolutions in brief: Resolution regarding the allocation of the company’s results (item 8 b) The Nomination Committee’s proposal (item 2 and 9 – 11)
Information about the persons proposed to be re-elected as board members is set forth in the company’s annual report as well as on the company’s website, www.modustx.com. Nomination committee (item 12)
Amendment of articles of association (item 13) § 4 Share capital § 5 Number of shares Share issue authorization (item 14) The board of directors proposes that the annual general meeting resolves to grant authorization to the board, for a period that does not extend past the date of the next annual general meeting, on one or several occasions, with or without pre-emptive rights for the shareholders, to resolve on the issue of new shares, convertibles and/or warrants. It shall also be possible to make such an issue resolution stipulating in-kind payment, the right to offset debt or other conditions. The purpose of the authorization is to enable the financing, commercialization and development of the company’s projects and to provide flexibility in commercial negotiations. Bonus agreement (item 15) The board of directors proposes that the annual general meeting resolves to grant authorization to the board, for a period that does not extend past the date of the next annual general meeting, on one or more occasions, to on behalf of the company enter into exit bonus agreements with senior executives and other key persons for the purpose of retaining such persons and to offer the appropriate incentives in relation to the continued development of the company. Through the exit bonus agreements, the senior executives and key persons covered by the agreements may together receive not more than 10 percent of the consideration after transaction costs if (i) the company’s shares or assets are acquired or out-licensed, and (ii) the consideration for such sale/licensing exceeds SEK 270 million. If the consideration for such sale/licensing exceeds SEK 1,500 million after transaction costs, senior executives and key persons covered by the bonus agreement may together receive not more than 10 percent of the part of the consideration that is less than SEK 1,500 million and 5 percent of the part of the consideration that exceeds SEK 1,500 million. _______________________ Processing of personal data Other Stockholm in April 2024 Modus Therapeutics Holding AB (publ) The Board of Directors |
||||
2024-04-11 | Modus Therapeutics Holding | Modus Therapeutics Holding AB (publ) offentliggör årsredovisning för räkenskapsåret 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-11 | Modus Therapeutics Holding | Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-28 | Penser Future by Carnegie | Penser Future by Carnegie: Modus Therapeutics Holding - Skuldfria och breddad portfölj | Pressreleaser | Visa Stäng |
|
||||
2024-02-21 | Modus Therapeutics Holding | Modus Therapeutics offentliggör bokslutskommuniké för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Modus Therapeutics Holding | Modus Therapeutics publishes year-end report for 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-12-13 | Modus Therapeutics Holding | The Rights Issue is Registered and Trading in Paid Subscribed Shares Ceases | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-13 | Modus Therapeutics Holding | Företrädesemissionen är registrerad och handel med BTA upphör | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-11 | Modus Therapeutics Holding | Modus Therapeutics presenterade data om sevuparin som visar dess potential att behandla anemi vid kronisk njursjukdom vid det årliga mötet American Society of Hematology (ASH) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-11 | Modus Therapeutics Holding | Modus Therapeutics presented data on sevuparin demonstrating its potential to treat anemia in chronic kidney disease at the annual American Society of Hematology (ASH) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-05 | Modus Therapeutics Holding | Modus Therapeutics Holding AB offentliggör slutligt utfall i företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-05 | Modus Therapeutics Holding | Modus Therapeutics Holding AB Announces Final Outcome in Rights Issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Modus Therapeutics Holding | Modus Therapeutics presenterar vid Erik Penser Banks Bolagsdag | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Modus Therapeutics Holding | Modus Therapeutics bjuder in till livesänd vd-intervju med fokus på förestående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Modus Therapeutics Holding | Modus Therapeutics Holding AB offentliggör prospekt med anledning av förestående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Modus Therapeutics Holding | Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Modus Therapeutics Holding | Modus Therapeutics Holding AB genomför företrädesemission om 40,3 MSEK och kvittningsemission om 20,3 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Modus Therapeutics Holding | Modus Therapeutics Holding AB Conducts a Rights Issue of 40.3 MSEK and an Offset Issue of 20.3 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Modus Therapeutics Holding | Modus Therapeutics offentliggör delårsrapport för tredje kvartalet 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Modus Therapeutics Holding | Modus Therapeutics publishes interim report for the third quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-02 | Modus Therapeutics Holding | Modus Therapeutics presenterar vid American Society of Hematology Meeting and Exposition 2023 (ASH): Nya data med sevuparin och dess potential att behandla anemi vid kronisk njursjukdom och minska njurskada. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-02 | Modus Therapeutics Holding | Modus Therapeutics to present at the 2023 American Society of Hematology Meeting and Exposition (ASH): New data on sevuparin and its potential to treat chronic kidney disease anemia and reduce kidney injury. | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Modus Therapeutics Holding | Modus Therapeutics presenterar slutliga data från sin Fas 1b LPS-provokationsstudie med sevuparin vid den årliga ISICIP-kongressen i Barcelona | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Modus Therapeutics Holding | Modus Therapeutics presents final data from its Phase 1b LPS-provocation study with sevuparin at the annual ISICIP symposium in Barcelona | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-31 | Penser Future | Penser Future: Intervju med Modus Therapeutics - Erik Penser Bank - 16 augusti 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-08-24 | Penser Future | Penser Future: Breddar IP-portföljen - Modus Therapeutics Holding | Pressreleaser | Visa Stäng |
|
||||
2023-08-23 | Modus Therapeutics Holding | Modus Therapeutics publishes interim report for the second quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-23 | Modus Therapeutics Holding | Modus Therapeutics offentliggör delårsrapport för andra kvartalet 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Penser Future | Penser Future: Hög potential till hög risk - Modus Therapeutics Holding | Pressreleaser | Visa Stäng |
|
||||
2023-06-12 | Modus Therapeutics Holding | Modus Therapeutics presented new data on sevuparin demonstrating its potential to treat anemia related to chronic diseases at the annual European Hematology Association Congress | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-12 | Modus Therapeutics Holding | Modus Therapeutics presenterade nya data som visar på potentialen för sevuparin som behandling vid anemi relaterad till kroniska sjukdomar på den årliga kongressen European Hematology Association Congress | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-12 | Modus Therapeutics Holding | Modus Therapeutics presenterar på den årliga kongressen European Hematology Association. Nya data med sevuparin ger potential att behandla anemi vid kronisk sjukdom genom att hämma hepcidin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-12 | Modus Therapeutics Holding | Modus Therapeutics to present at the annual European Hematology Association Congress, new data on sevuparin and its potential to treat anemia of chronic disease by suppression of hepcidin | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-11 | Modus Therapeutics Holding | Årsstämma i Modus Therapeutics Holding AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-11 | Modus Therapeutics Holding | Annual General Meeting in Modus Therapeutics Holding AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | Modus Therapeutics Holding | Modus Therapeutics publishes interim report for the first quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | Modus Therapeutics Holding | Modus Therapeutics offentliggör delårsrapport för första kvartalet 2023 | Rapporter | Ladda ner | Visa Stäng |
|